These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 26446378)
61. Emerging technologies in solid drug delivery: an interview with Nadia Passerini. Passerini N Ther Deliv; 2017 Jan; 8(3):121-124. PubMed ID: 28145825 [TBL] [Abstract][Full Text] [Related]
62. Interview with faz chowdhury. Chowdhury F Ther Deliv; 2014 Jun; 5(6):631-3. PubMed ID: 25090277 [TBL] [Abstract][Full Text] [Related]
63. Bendamustine for non-Hodgkin lymphoma. Interview by Louise Rishton. Gribben J Expert Rev Hematol; 2013 Apr; 6(2):123-5. PubMed ID: 23547860 [TBL] [Abstract][Full Text] [Related]
64. Hierarchically porous materials and green chemistry-an interview with Ming-Yuan He. Chen LH Natl Sci Rev; 2020 Nov; 7(11):1759-1761. PubMed ID: 34691506 [TBL] [Abstract][Full Text] [Related]
65. The therapeutic potential of CD39: interview with Dr Simon Robson by Emma Quigley. Robson S Expert Opin Ther Targets; 2006 Oct; 10(5):649-52. PubMed ID: 16981822 [TBL] [Abstract][Full Text] [Related]
66. Transitioning biomarkers into the clinic. Waldman SA Expert Rev Clin Pharmacol; 2009 Jan; 2(1):9-13. PubMed ID: 24422768 [TBL] [Abstract][Full Text] [Related]
67. Redesigner drugs. Dove A Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643 [TBL] [Abstract][Full Text] [Related]
68. Target selection and pharma industry productivity: what can we learn from technology S-curve theory? Brown D Curr Opin Drug Discov Devel; 2006 Jul; 9(4):414-8. PubMed ID: 16889225 [TBL] [Abstract][Full Text] [Related]
69. Cell adhesion molecules as therapeutic targets: interview with Professor Michael P Schön. Interviewed by Emma Quigley. Schön MP Expert Opin Ther Targets; 2006 Dec; 10(6):799-802. PubMed ID: 17105368 [TBL] [Abstract][Full Text] [Related]
70. Interview with Avedis Donabedian, M.D. Interview by Gordon Brown. Donabedian A Am J Med Qual; 1996; 11(4):167-72. PubMed ID: 8972932 [TBL] [Abstract][Full Text] [Related]
71. Bob Ruffolo discusses the rhythm of drug development. Ruffolo B Drug Discov Today; 2004 Aug; 9(15):631-5. PubMed ID: 15279843 [TBL] [Abstract][Full Text] [Related]
72. Deal watch: MSD buys in to emerging epigenetic cancer target. Cully M Nat Rev Drug Discov; 2016 Mar; 15(3):153. PubMed ID: 26931086 [No Abstract] [Full Text] [Related]
73. Interview with Frank Ivy Carroll. Carroll FI; Coaker H Future Med Chem; 2013 Jun; 5(10):1083-8. PubMed ID: 23795966 [TBL] [Abstract][Full Text] [Related]
75. Targeted drug therapy remains a challenge. Traynor K Am J Health Syst Pharm; 2011 Dec; 68(24):2320-4. PubMed ID: 22135055 [No Abstract] [Full Text] [Related]
76. The Virtual Liver Network: systems understanding from bench to bedside. Henney A; Coaker H Future Med Chem; 2014; 6(16):1735-40. PubMed ID: 25574529 [TBL] [Abstract][Full Text] [Related]
77. Reflections on Randomized Trials and Observational Studies: "Big Is Beautiful" A Conversation With Sir Rory Collins, FRS. Collins SR; Rutherford JD Circulation; 2019 Jul; 140(1):4-10. PubMed ID: 31549872 [TBL] [Abstract][Full Text] [Related]
78. Early career researchers: an interview with Graham Scott. J Exp Biol; 2017 Aug; 220(Pt 16):2845-2847. PubMed ID: 28814607 [TBL] [Abstract][Full Text] [Related]
79. Insights into Ayurvedic biology-sA conversation with Professor M.S. Valiathan. Joshi K J Ayurveda Integr Med; 2012 Oct; 3(4):226-9. PubMed ID: 23326096 [TBL] [Abstract][Full Text] [Related]